Лидевин is used to support the treatment of chronic alcohol dependence in adults. The drug is considered an adjunct therapy and is typically used within a comprehensive management program that includes medical supervision and counseling.

Quick Facts: Лидевин Therapeutic Domain

• Chronic Alcohol Dependence
• Abstinence Support
• Deterrent to Alcohol Consumption

The benefit of this treatment is its ability to create a strong deterrent effect. If a patient consumes alcohol while undergoing treatment, the resulting buildup of an alcohol metabolite, acetaldehyde, produces immediate and unpleasant physical symptoms, such as flushing, nausea, vomiting, and headache. This aversive reaction is intended to discourage further alcohol ingestion. Treatment with disulfiram, the active component, is often considered for highly motivated patients and is most effective when administered under supervision to ensure adherence.

Regulatory References

1. NIH MedlinePlus guidance on disulfiram

Who Can and Cannot Use Лидевин?

Eligibility for Лидевин (Disulfiram) use is strictly defined by regulatory documents and depends on the patient's current health status and recent alcohol consumption. The drug is approved primarily for use in adults for the management of chronic alcohol use disorder.

---

Absolute Contraindications

Use is contraindicated and absolutely prohibited in several patient populations, including those with:

• Severe myocardial disease or coronary occlusion.
• Psychoses or manifest psychoses.
• Severe hepatic or renal disease.
• Known hypersensitivity to disulfiram or thiuram derivatives.
• Concurrent use of metronidazole or paraldehyde.

Additionally, the medication must not be used by anyone who is currently alcohol-intoxicated or who has consumed alcohol within the preceding 12 to 24 hours.

---

Population Restrictions

Population Group	Regulatory Status
Pediatric Use	Safety and effectiveness have not been established in children.
Pregnancy	Contraindicated by some regulators; safe use is not established.
Lactation	Not recommended due to unknown excretion in breast milk.
Conditional Use	Patients with diabetes mellitus, epilepsy, or mild hepatic insufficiency require specific caution.

Geriatric patients are eligible, but the official labeling recommends cautious dose selection due to potential age-related organ function decline.

Interactions with Other Medicines and Products

Лидевин (Lidevin) contains disulfiram and is associated with several important drug interactions, primarily due to the mechanism of the disulfiram component. It is essential to be aware of these combinations to maintain safety.

Contraindicated Combination

• Alcohol (Ethanol): The combination with any source of alcohol (including beverages, food, or alcohol-containing medicines) is strictly contraindicated. This combination leads to a severe intolerance reaction known as the disulfiram-ethanol reaction, which involves symptoms like flushing, nausea, vomiting, rapid heartbeat, and a drop in blood pressure. Treatment must not be initiated until at least 12 to 24 hours after the last alcohol intake.

Combinations Requiring Close Monitoring or Dose Adjustment

The disulfiram component can affect the metabolism of several other medicines, potentially increasing their concentration and risk of toxicity. Therefore, close clinical monitoring and dose adjustments are generally required for the following drug classes:

• Benzodiazepines (e.g., Diazepam, Chlordiazepoxide): Disulfiram can inhibit the metabolism of certain benzodiazepines, which may lead to enhanced sedation and central nervous system effects. A reduction in the benzodiazepine dose may be necessary.
• Tricyclic Antidepressants (TCAs): Combining these can potentially increase the severity of the disulfiram-ethanol reaction if alcohol is consumed. Additionally, there are reports suggesting a risk of delirium and changes in TCA levels that necessitate caution and possible dose modification.
• Theophylline: The metabolism of theophylline can be inhibited, leading to increased plasma levels and a greater risk of theophylline-related toxicity. Theophylline dosage typically requires adjustment based on blood levels and clinical response.

Note: Other medicines that rely on similar metabolic pathways may also require monitoring when used concurrently.

The mechanism of action of Лидевин is derived from its core component, Disulfiram, which modifies the body's method of breaking down ethanol by targeting a specific detoxification enzyme.

Irreversible Blockade of Alcohol Metabolism

The mechanism involves the irreversible inhibition of the mitochondrial enzyme Aldehyde Dehydrogenase ( ALDH). Disulfiram's active metabolite, diethyldithiocarbamate ( DDTC), forms a covalent bond with a cysteine residue in the ALDH enzyme, resulting in its permanent inactivation. This molecular blockade prevents the second oxidative step of ethanol metabolism: the conversion of the intermediate Acetaldehyde into Acetate.

The Acetaldehyde Accumulation Cascade

Upon consuming ethanol, the inhibited ALDH cannot metabolize the Acetaldehyde, causing a rapid and massive systemic accumulation of this substance. This Acetaldehyde acts as an active pharmacological agent, directly triggering profound vasodilation (flushing, blood pressure drop) and stimulating chemoreceptors, which initiates a severe physiological response. The cellular requirement for the synthesis of new ALDH enzymes dictates that this high sensitivity persists for up to two weeks after the final dose.

Supportive Cofactor Pathway

The formulation includes Nicotinamide and Adenine, precursors to the metabolic cofactor NAD^+. While NAD^+ is critical for cellular processes, there is no established evidence that these supplementary components enhance the core ALDH inhibition mechanism responsible for the immediate physiological reaction.

Лидевин is an oral medication taken strictly under a continuous, long-term regimen to support abstinence. The usage protocol requires strict adherence to dose and timing, as detailed in official prescribing information.

Official Administration Guidelines

Field	Detail
Route of Administration	Oral (by mouth)
Required Pre-treatment	Administration must not begin until the patient has achieved at least 12 hours of confirmed alcohol abstinence.
Frequency and Timing	Administered as a single dose once daily, usually in the morning. Taking it at bedtime is permissible if the patient experiences a sedative effect.

Standard Labeled Dosing Regimen

The standard adult use protocol involves an initial dose followed by a long-term maintenance phase:

• Initial Dose: A maximum of 500 mg daily is administered once daily for a period lasting one to two weeks.
• Maintenance Dose: The dose is subsequently reduced to an average of 250 mg daily. The labeled maintenance range is 125 mg to 500 mg daily, and the total daily dose should never exceed 500 mg.

Procedural and Course Structure

The treatment course is defined as a long-term therapy that should be continued daily and without interruption for months or even years, until a secure basis for permanent self-control has been established. For patients who struggle with adherence, the official instructions permit the tablet to be crushed and well mixed with liquids (such as water, coffee, or juice) to facilitate intake under supervision. For older adults, dose selection should be cautious, typically starting at the low end of the official dosing range.

Research evidence / Overview of studies for Лидевин

This overview summarizes the formal clinical research and studies that have been conducted on Disulfiram, the active ingredient in Лидевин, in the context of Alcohol Use Disorder (AUD) studies. It describes what researchers have studied, the types of outcomes they measured, and where the limitations or gaps in the current research exist.

---

Evidence for use in Chronic Alcohol Dependence and Abstinence Support

Studies exploring the use of Disulfiram have primarily focused on patients with Chronic Alcohol Dependence (AUD), and research examined whether it was associated with continuous abstinence. The main body of research consists of controlled trials, including both traditional Randomized Controlled Trials (RCTs) and open-label studies, alongside meta-analyses that combine data from various trials.

Researchers explored outcomes related to physical discomfort and outcomes reflecting daily functioning, specifically measuring the rates of abstinence achieved by observed populations and the time elapsed before a relapse episode. Studies also monitored changes in the overall consumption of alcohol throughout the observation periods. Findings describe patterns observed in the studies that often differed significantly depending on how the medication was administered in the trial setting.

The Role of Supervision in Clinical Trials

One major focus of research examined the focus on the setting where patients' intake was monitored by researchers. When studies explored settings where Disulfiram intake was daily and supervised (meaning a healthcare provider, family member, or observer confirmed the dose was taken), the measured outcomes reported patterns related to continued abstinence. Research highlights changes measured during the study period when supervision was involved.

Conversely, findings were mixed in trials where medication was taken unsupervised. The evidence derived from these settings indicates that patterns of abstinence were associated with verifiable compliance in the studies. Research patterns were most consistently described in highly controlled scenarios, which are difficult to replicate in all daily-life functioning situations.

Long-term Research and Follow-up Durations

There is limited information for long-term outcomes that look at the durability of abstinence maintenance over several years. Some observational settings evaluating daily-life functioning using patient registries have been observed over longer periods, but these types of studies do not provide the same level of insight as controlled clinical trials. Evidence contributes to the broader evidence landscape but certainty remains low regarding outcomes after the first year.

Key Limitations and Areas of Research Uncertainty

The research conducted so far contributes to describing the patterns observed in the studies, but several key limitations exist. One challenge studies faced is the methodological difficulty of blinding (hiding the treatment identity) in traditional clinical trials due to the medication’s unique and predictable physical reaction to alcohol. This often meant that the studies that showed the clearest patterns were open-label trials. The evidence quality varies across studies, largely due to differences in compliance monitoring and the inclusion of supportive counseling services.

Common questions about Лидевин (FAQ)

Q: Does Лидевин help reduce the urge to drink alcohol?

Studies and official information indicate that the active substance in Лидевин, disulfiram, is intended to help reduce the urge for continued alcohol consumption by affecting the body's metabolism of alcohol. Regulatory documents state that this medicine is used as a tool in the treatment of chronic alcoholism.

Q: How long does the effect of Лидевин last after one tablet?

According to the official product information, the biochemical effect of the active substance remains detectable for 7 to 14 days after the last intake. Official product information notes that the sustained effect allows for use on an intermittent or spaced-out schedule, as directed by a healthcare professional.

Q: Is Лидевин effective for treating acute alcohol intoxication (being currently drunk)?

Regulatory documents state that Лидевин is specifically indicated for the treatment of chronic alcoholism (long-term, persistent alcohol dependence). It is not indicated or intended for the treatment of acute alcohol intoxication (drunkenness) or alcohol withdrawal syndrome.

Q: Can I eat while taking Лидевин?

Official product information suggests taking the tablet in the morning on an empty stomach. Official product information does not list restrictions on food intake after the tablet is taken, but the recommendation is related to the timing of administration.

How to Store and Dispose of Лидевин (Disulfiram Tablets)

Official regulatory information details the required storage conditions to ensure the quality and stability of Лидевин tablets.

Storage Conditions

Requirement	Official Stipulation
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection	Keep away from excess heat, moisture, and direct light.
Container	Must be kept in the container it was dispensed in and kept tightly closed.
Child Safety	Keep this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Лидевин must be disposed of according to local regulatory requirements. Do not dispose of the medication via wastewater or household waste. Proper disposal measures are required to protect the environment.